DK2441465T3 - Præparater og fremgangsmåder til en sund graviditet - Google Patents

Præparater og fremgangsmåder til en sund graviditet

Info

Publication number
DK2441465T3
DK2441465T3 DK11178173.8T DK11178173T DK2441465T3 DK 2441465 T3 DK2441465 T3 DK 2441465T3 DK 11178173 T DK11178173 T DK 11178173T DK 2441465 T3 DK2441465 T3 DK 2441465T3
Authority
DK
Denmark
Prior art keywords
methods
kits
preparations
prevention
present
Prior art date
Application number
DK11178173.8T
Other languages
English (en)
Inventor
Darryl L Carter
Original Assignee
Nora Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nora Therapeutics Inc filed Critical Nora Therapeutics Inc
Application granted granted Critical
Publication of DK2441465T3 publication Critical patent/DK2441465T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
DK11178173.8T 2003-10-24 2004-10-25 Præparater og fremgangsmåder til en sund graviditet DK2441465T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51447203P 2003-10-24 2003-10-24
EP04796441A EP1682074B1 (en) 2003-10-24 2004-10-25 Compositions and methods for healthy pregnancy

Publications (1)

Publication Number Publication Date
DK2441465T3 true DK2441465T3 (da) 2014-04-14

Family

ID=34520212

Family Applications (4)

Application Number Title Priority Date Filing Date
DK10159565.0T DK2213295T3 (da) 2003-10-24 2004-10-25 Fremgangsmåde til opnåelse af data, som er nyttige til identifikation af en patient, som er udsat for risiko for at have vanskeligheder ved at opretholde en graviditet
DK11178173.8T DK2441465T3 (da) 2003-10-24 2004-10-25 Præparater og fremgangsmåder til en sund graviditet
DK04796441.6T DK1682074T3 (da) 2003-10-24 2004-10-25 Præparater og fremgangsmåder til sund graviditet
DK10155709.8T DK2198876T3 (da) 2003-10-24 2004-10-25 Fremgangsmåde til nedsættelse af sandsynligheden for implantationssvigt i et individ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10159565.0T DK2213295T3 (da) 2003-10-24 2004-10-25 Fremgangsmåde til opnåelse af data, som er nyttige til identifikation af en patient, som er udsat for risiko for at have vanskeligheder ved at opretholde en graviditet

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK04796441.6T DK1682074T3 (da) 2003-10-24 2004-10-25 Præparater og fremgangsmåder til sund graviditet
DK10155709.8T DK2198876T3 (da) 2003-10-24 2004-10-25 Fremgangsmåde til nedsættelse af sandsynligheden for implantationssvigt i et individ

Country Status (6)

Country Link
US (11) US7470662B2 (da)
EP (7) EP1682074B1 (da)
AT (1) ATE544460T1 (da)
DK (4) DK2213295T3 (da)
ES (4) ES2405255T3 (da)
WO (1) WO2005039505A2 (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338373B2 (en) 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
ES2405255T3 (es) 2003-10-24 2013-05-30 Nora Therapeutics, Inc. Un método para reducir la probabilidad del fracaso de la implantación en un sujeto
US20090226397A1 (en) 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
US20100150862A1 (en) * 2006-12-07 2010-06-17 Schering Corporation Methods of modulating maternal-fetal tolerance
US20110171168A1 (en) * 2008-05-13 2011-07-14 Nora Therapeutics, Inc. Human g-csf analogs and methods of making and using thereof
WO2009139784A1 (en) * 2008-05-13 2009-11-19 Nora Therapeutics, Inc. Human g-csf analogs and methods of making and using thereof
WO2010011767A2 (en) 2008-07-22 2010-01-28 Duke Debra M Compositions and methods for treating symptoms associated with menopause, hormonal variations and arthritis
US9151289B2 (en) 2008-08-21 2015-10-06 Cummins Inc. Fuel pump
WO2010126528A1 (en) * 2009-05-01 2010-11-04 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
EP2475127A1 (en) * 2011-01-10 2012-07-11 Panasonic Corporation Channel state information reporting for component carriers for which no channel state information was calculated
US11717499B2 (en) * 2011-06-28 2023-08-08 Sandra Eve Reznik Administration of N,N-dimethylacetamide for the treatment of preterm birth
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
WO2013113658A1 (en) * 2012-01-31 2013-08-08 Vitrolife Sweden Ab Media
CA2873968A1 (en) * 2012-05-16 2014-06-26 Kennedy Krieger Institute, Inc. Stem cells as an individualized maternal therapy for prevention of prematurity
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
AU2013311289B2 (en) * 2012-09-04 2017-11-16 Pluristem Ltd. Methods for prevention and treatment of preeclampsia
ITMI20121562A1 (it) * 2012-09-19 2014-03-20 Marco Sbracia Utilizzo di g-csf nella coltura in vitro di embrioni
ITMI20122063A1 (it) 2012-12-03 2014-06-04 Marco Sbracia Gm-csf per l'utilizzo nella prevenzione dell'aborto spontaneo e del fallimento dell'impianto dell'embrione
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
WO2015057724A1 (en) * 2013-10-14 2015-04-23 Nora Therapeutics, Inc. Use of g-csf for treating or preventing villitis of unknown etiology in a human female
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CN110169717A (zh) * 2017-08-09 2019-08-27 沙克忍者运营有限责任公司 烹饪系统
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
US11678765B2 (en) 2020-03-30 2023-06-20 Sharkninja Operating Llc Cooking device and components thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1A (en) * 1836-07-13 John Ruggles Locomotive steam-engine for rail and other roads
US6150085A (en) 1998-09-16 2000-11-21 The United States Of America As Represented By The Secretary Of The Army Prolonged storage of red blood cells and composition
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5908763A (en) 1984-07-06 1999-06-01 Novartis Corporation DNA encoding GM-CSF and a method of producing GM-CSF protein
UA29377C2 (uk) 1984-09-19 2000-11-15 Новартіс Аг Спосіб отримання білка з активністю колонієстимулювального фактора гранулоцитів та макрофагів(gm-csf) приматів
US5888495A (en) * 1988-05-23 1999-03-30 Genetics Institute, Inc. Method of producing storage stable M-CSF lyophilizates
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
US6166183A (en) 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
IE66494B1 (en) 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
US5714140A (en) * 1989-12-13 1998-02-03 Otsuka Pharmaceutical Co., Ltd. Method for inhibiting the production of bioactive IL-1 by administering M-CSF
US5147799A (en) * 1990-04-25 1992-09-15 Isia Bursuker Repopulation of macrophages and granulocytes using transforming growth factor-beta
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
US5399345A (en) 1990-05-08 1995-03-21 Boehringer Mannheim, Gmbh Muteins of the granulocyte colony stimulating factor
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5276017A (en) * 1990-09-14 1994-01-04 Trustees Of The University Of Pennsylvania Therapeutic and diagnostic applications of tropho-uteronectin (TUN) manipulation
WO1992016192A1 (en) 1991-03-15 1992-10-01 Amgen Inc. Pulmonary administration of granulocyte colony stimulating factor
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
DE4242919A1 (de) 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
CA2183266A1 (en) * 1994-02-14 1995-08-17 Richard D. Holly Hematopoietic protein and materials and methods for making it
DE19549232C2 (de) * 1995-12-20 1998-05-20 Boehringer Mannheim Gmbh Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern
US6040340A (en) * 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
NZ332823A (en) 1996-05-22 2000-05-26 Smithkline Beecham Corp ,5-Diimino-3a,6a-diaryl-1,2,3,3a,4,5,6,6a-octahydroimi dazo[4,5-d]imidazoles as non-peptide G-CSF mimetics
US6197743B1 (en) * 1996-07-26 2001-03-06 The Trustees Of Boston University Compositions and methods for the treatment of viral disorders
US5766944A (en) * 1996-12-31 1998-06-16 Ruiz; Margaret Eileen T cell differentiation of CD34+ stem cells in cultured thymic epithelial fragments
US6162417A (en) 1997-05-07 2000-12-19 Emory University Pyrrolo isoquinolines
EP1198245B1 (en) * 1998-09-30 2004-08-25 Walter Reed Army Institute of Research Use of purified invaplex from gram negative bacteria as a vaccine
US6245740B1 (en) * 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
KR100356140B1 (ko) * 1999-07-08 2002-10-19 한미약품공업 주식회사 인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
AU2001245463A1 (en) * 2000-03-07 2001-09-17 Millennium Pharmaceuticals, Inc. 26583, a novel serine/threonine phosphatase and uses therefor
DK1317537T3 (da) * 2000-09-08 2007-04-30 Massachusetts Inst Technology Sammensætninger og fremgangsmåder med G-CSF analoger
US7718387B2 (en) * 2001-09-20 2010-05-18 Board Of Regents, The University Of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
DK1578771T3 (da) * 2001-10-10 2013-06-10 Novo Nordisk As Remodellering og glycokonjugering af peptider
US20040105858A1 (en) * 2002-08-29 2004-06-03 Kim Joanne Young Hee Kwak Diagnosis and treatment of infertility
ES2405255T3 (es) 2003-10-24 2013-05-30 Nora Therapeutics, Inc. Un método para reducir la probabilidad del fracaso de la implantación en un sujeto
US20090226397A1 (en) 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
WO2006128176A2 (en) 2005-05-26 2006-11-30 Nora Llc Composite molecules comprising g-csf function
MY150687A (en) 2006-07-21 2014-02-28 Femalon S P R L Assay and kit for predicting implantation success in assisted fertilisation

Also Published As

Publication number Publication date
EP2213295B1 (en) 2013-01-23
ES2458219T3 (es) 2014-04-30
US7824712B2 (en) 2010-11-02
EP2441465A1 (en) 2012-04-18
US20100158971A1 (en) 2010-06-24
US20120269763A1 (en) 2012-10-25
US20090028819A1 (en) 2009-01-29
ATE544460T1 (de) 2012-02-15
EP2198876B1 (en) 2012-12-05
EP1682074A2 (en) 2006-07-26
US7470662B2 (en) 2008-12-30
US20080213301A1 (en) 2008-09-04
US20110229436A1 (en) 2011-09-22
ES2405255T3 (es) 2013-05-30
EP2198876A1 (en) 2010-06-23
EP2213295A1 (en) 2010-08-04
EP1682074A4 (en) 2009-07-08
US7615531B2 (en) 2009-11-10
US20090081160A1 (en) 2009-03-26
ES2381884T3 (es) 2012-06-01
US20100158972A1 (en) 2010-06-24
EP2441465B1 (en) 2014-01-15
US20090035262A1 (en) 2009-02-05
ES2405506T3 (es) 2013-05-31
EP2196210A1 (en) 2010-06-16
US20070071716A1 (en) 2007-03-29
EP1682074B1 (en) 2012-02-08
DK2198876T3 (da) 2013-03-11
US7700548B2 (en) 2010-04-20
WO2005039505A3 (en) 2007-12-13
US8481488B2 (en) 2013-07-09
EP2198875A1 (en) 2010-06-23
US20080213211A1 (en) 2008-09-04
US20090035263A1 (en) 2009-02-05
DK2213295T3 (da) 2013-05-06
DK1682074T3 (da) 2012-05-29
EP2140875A1 (en) 2010-01-06
WO2005039505A2 (en) 2005-05-06
US7744864B2 (en) 2010-06-29
US7939491B2 (en) 2011-05-10

Similar Documents

Publication Publication Date Title
DK2441465T3 (da) Præparater og fremgangsmåder til en sund graviditet
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
EA200500232A1 (ru) Способы диагностики и лечения преэклампсии или эклампсии
MXPA05014166A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
HUP0302384A2 (hu) Sejtek bioenergia metabolizmusában szerepet játszó biokémiai vegyületeket tartalmazó készítmények és alkalmazásuk
NO20055130D0 (no) Aminocykloheksyleter-forbindelser og deres anvendelse
ATE540129T1 (de) Target zur therapie kognitiver behinderungen
DK1155019T3 (da) Substituerede porphyriner og deres terapeutiske anvendelse
WO2002080754A3 (en) Methods for using annexin for detecting cell death in vivo and treating associated conditions
WO2003088917A3 (en) Regulation of tnf-alpha
EE200300366A (et) Meetodid nahahaiguste ravimiseks või tõkestamiseks CD2-siduvate vahendite abil
WO2002092013A3 (en) Methods for treating liver disease and liver damage with growth hormone and foxm1b
AU2002365057A8 (en) Compositions and methods for treating heart failure
DE60329326D1 (de) Tace inhibitoren
EP1450820A4 (en) METHOD OF TREATING AND PREVENTING INFLAMMATORY DISEASES
AU2001251507A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
EP1801232A4 (en) METHOD FOR SORTING TRANSMEMBRANE ENZYME INHIBITOR SUBSTANCE
WO2004060878A3 (en) Inhibitors of phosphatases
WO2002062205A3 (en) Methods for diagnosing and treating heart disease
AU2001251508A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
AU2001256998A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
ATE319689T1 (de) Naphthamidin-urokinasinhibitoren
WO2007067516A3 (en) Multiple myeloma
SE0100873D0 (sv) Method of treatment
WO2003023048A3 (en) METHODS FOR DIAGNOSING AND TREATING DISEASES AND CONDITIONS ASSOCIATED WITH PROTEIN KINASE C$g(l)